CEBP Infection and Cancer: Biology, Therapeutics, and Prevention 2008 Conference on Cancer Prevention - Washington, D.C.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sitas, F.
Right arrow Articles by Forman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sitas, F.
Right arrow Articles by Forman, D.

Cancer Epidemiology Biomarkers & Prevention, Vol 2, Issue 2 119-123, Copyright © 1993 by American Association for Cancer Research


ARTICLES

Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis

F Sitas, R Smallwood, D Jewell, PR Millard, DG Newell, SG Meuwissen, S Moses, A Zwiers and D Forman
Cancer Epidemiology Unit, Imperial Cancer Research Fund, Oxford, England.

This study was designed to test the sensitivity and specificity of serum anti-Helicobacter pylori IgG antibodies and the ratio of serum pepsinogen A to pepsinogen C (PGA:PGC) in detecting chronic atrophic gastritis (CAG) and intestinal metaplasia. Parallel gastric biopsies and a serum sample were collected from a series of 87 patients aged 20-69 years attending a routine upper endoscopy clinic. The seroprevalence (> 10 micrograms IgG/ml) of anti-H. pylori antibodies was 42.7%, and of a low PGA:PGC ratio (< 1.5) was 17.7%. A positive H. pylori IgG antibody level was more sensitive than the level of PGA:PGC in diagnosing CAG (71.4% and 25.0%, respectively), moderate CAG (86.7% and 26.7%, respectively), and intestinal metaplasia (90.9% and 50.0%, respectively). Anti-H. pylori IgG antibody levels were less specific than PGA:PGC levels in diagnosing CAG (90.9% and 93.9%, respectively), moderate CAG (78.3% and 89.1%, respectively), and intestinal metaplasia (72.6% and 92.2%, respectively). A combination of anti-H. pylori antibodies and a low PGA:PGC ratio for the detection of CAG resulted in a specificity of 100%, but the sensitivity was 21.4%.


This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Ley, A. Mohar, J. Guarner, R. Herrera-Goepfert, L. S. Figueroa, D. Halperin, and J. Parsonnet
Screening Markers for Chronic Atrophic Gastritis in Chiapas, Mexico
Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 107 - 112.
[Abstract] [Full Text]


Home page
GutHome page
F Kitahara, K Kobayashi, T Sato, Y Kojima, T Araki, and M A Fujino
Accuracy of screening for gastric cancer using serum pepsinogen concentrations
Gut, May 1, 1999; 44(5): 693 - 697.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.